Clinical Study of Fangji Huangqi Decoction in Treating Chronic Heart Failure

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005429

Enrollment

Unknown

Registered

2021-12-20

Start date

2021-12-21

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Control group:Western medicine routine treatment

test group:Traditional western medicine treatment plus Fangji Huangqi Decoction

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of chronic heart failure in western medicine; (2) Comply with the syndrome differentiation standard of chronic heart failure with Qi deficiency and blood stasis combined with water in-drinking stop syndrome; (3) LVEF450ng/l; (4) NYHA classification of heart function is ?~?; (5) There is no restriction on gender; (6) 18 years old = age = 85 years old; (7) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with acute coronary syndrome, acute myocardial infarction within 6 months, patients with revascularization within 6 months, or patients with planned revascularization within 1 week, cardiogenic shock, fatal arrhythmia, Cardiomyopathy, rheumatic heart valve disease, myocarditis, constrictive pericarditis, pulmonary embolism, etc.; (2) Patients with severe liver and kidney dysfunction [ALT and or AST> 3 times the upper limit of the normal reference value; GFR <30ml/(min·1.73m2)]; (3) Combined with serious primary diseases such as endocrine system and hematopoietic system; (4) Women who are planning to give birth, pregnancy or lactation in the past 3 months; (5) Mental patients; (6) People with allergies, or those who are known to be allergic to this medicine and its ingredients; (7) Those who have participated in other clinical trials within the past 3 months. (8) The investigator judges that the survival period does not exceed 3 months; (9) The investigator judged that he could not complete the study or could not comply with the requirements of the study.

Design outcomes

Primary

Measure	Time frame
KCCQ;	—

Secondary

Measure	Time frame
NT-proBNP;Heart function classification (NYHA);Echocardiogram;6MWD;	—

Countries

China

Contacts

Public ContactYingqiang Zhao

zhaoyingqiang1000@126.com13920089969

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026